title: Human lower oesophageal sphincter relaxation is associated with raised cyclic nucleotide content.
abstract: Increases in cyclic adenosine monophosphate and cyclic guanosine monophosphate content accompany relaxation of isolated strips of opossum and canine lower oesophageal sphincter muscle. The aim of this investigation was to characterise these responses in isolated muscle from the human lower oesophageal sphincter. Electrical stimulation of enteric neurons produced a frequency dependent relaxation of the human lower oesophageal sphincter that was sensitive to tetrodotoxin. Furthermore, as previously shown in the opossum and canine lower oesophageal sphincter, cyclic guanosine monophosphate content was significantly raised in muscle strips frozen during maximum electrical field stimulation whereas cyclic adenosine monophosphate content was unchanged. In addition, sodium nitroprusside (EC50 = 0.1 microM) produced a concentration dependent relaxation of human lower oesophageal sphincter, significantly increased cyclic guanosine monophosphate content, but did not alter cyclic adenosine monophosphate content. Zaprinast (M&B 22948) and SK&F 94120, selective inhibitors of cyclic guanosine monophosphate and cyclic adenosine monophosphate phosphodiesterases, respectively, both relaxed human lower oesophageal sphincter with a potency similar to that seen in the dog or opossum lower oesophageal sphincter. Finally, the 8-bromo analogues of both cyclic adenosine monophosphate (EC50 = 420 microM) and cyclic guanosine monophosphate (EC50 = 100 microM) relaxed the human lower oesophageal sphincter. These studies suggest that in the human, as well as the canine and opossum lower oesophageal sphincter, increases in cyclic nucleotide content are associated with relaxation and increases in cyclic guanosine monophosphate are associated with the relaxation induced by stimulation of enteric neurons.
authors.affiliation: Department of Pharmacology, Smith Kline and French Laboratories, King of Prussia, Pennsylvania.
authors.forename: M S
authors.initials: MS
authors.lastname: Barnette
authors.forename: F C
authors.initials: FC
authors.lastname: Barone
authors.forename: P J
authors.initials: PJ
authors.lastname: Fowler
authors.forename: M
authors.initials: M
authors.lastname: Grous
authors.forename: W J
authors.initials: WJ
authors.lastname: Price
authors.forename: H S
authors.initials: HS
authors.lastname: Ormsbee
mesh_terms: D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D004558:Electric Stimulation; D004943:Esophagogastric Junction / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D009126:Muscle Relaxation / Q000187:drug effects / Q000502:physiology*; D009599:Nitroprusside / Q000494:pharmacology; D009712:Nucleotides, Cyclic / Q000378:metabolism*; D011688:Purinones / Q000494:pharmacology; D011719:Pyrazines / Q000494:pharmacology; D013779:Tetrodotoxin / Q000494:pharmacology
chemical_list: D009712:Nucleotides, Cyclic; D011688:Purinones; D011719:Pyrazines; D009599:Nitroprusside; D015124:8-Bromo Cyclic Adenosine Monophosphate; C016276:8-bromocyclic GMP; D013779:Tetrodotoxin; C048350:5-(4-acetamidophenyl)pyrazin-2(1H)-one; D000242:Cyclic AMP; C011145:zaprinast; D006152:Cyclic GMP